ERBB2 and breast cancer: Although patients with HER2 2+ breast cancer were more likely to have higher NLRs than those with HER2 3+ breast cancer (P=0.06), a trend toward lower PLRs was demonstrated for overweight/obese patients, compared with underweight/normal weight patients (P=0.055).